证券之星消息，近日济民健康（维权）披露，截至2025年6月30日公司股东户数为2.81万户，较3月31日 增加388.0户，增幅为1.4%。户均持股数量由上期的1.9万股减少至1.87万股，户均持股市值为12.81万 元。 在医疗器械行业个股中，济民健康股东户数高于行业平均水平，截至6月30日，医疗器械行业平均股东 户数为2.2万户。户均持股市值方面，医疗器械行业A股上市公司户均持股市值为46.49万元，济民健康 低于行业平均水平。 | | | 统计截止日 区间股价涨跌幅 股东户数 增减 增减比例 户均持股市值（元） | | | 户均持股数(股) | | --- | --- | --- | --- | --- | --- | | 2025-06-30 | 13.04% | 28075 388 | 1.40% | 12.81万 | 1.87万 | | 2025-03-31 | -10.75% | 27687 -483 | -1.71% | 11.49万 | 1.90万 | | 2024-12-31 | 2.41% | 28170 -4881 | -14.77% | 12.66万 | 1.86万 | | 2024 ...

二、经营业绩风险 证券代码：603222 证券简称：济民健康 公告编号：2025-039 济民健康管理股份有限公司 股票交易风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 济民健康管理股份有限公司（以下简称"公司"）股票自 2025 年 8 月 13 日 至 2025 年 8 月 19 日，公司股票收盘价格累计涨幅达 53.78%，并连续两次触及异 动。2025 年 8 月 20 日，公司股票再次涨停，换手率达到 31.31%，上述指标均远 高于行业同期平均水平。公司基本面未发生重大变化，存在市场情绪过热及非理 性炒作的情形，公司股票击鼓传花效应明显，存在较大交易风险，公司股价短期 涨幅较大，后续股票可能存在较大下跌风险。公司郑重提醒广大投资者注意投资 风险，理性决策、审慎投资。 一、二级市级交易风险 自2025年8月13日至2025年8月19日，公司股票收盘价格累计涨幅达53.78%， 并连续两次触及异动。2025 年 8 月 20 日，公司股票再次涨停，换手率达到 31.31%， 上述指标均远高于行业同 ...

经济观察网 济民健康（603222）公告，公司股票自2025年8月13日至2025年8月19日，收盘价格累计涨 幅达53.78%，并连续两次触及异动。2025年8月20日，公司股票再次涨停，换手率达到31.31%。公司基 本面未发生重大变化，存在市场情绪过热及非理性炒作的情形，公司股票击鼓传花效应明显，存在较大 交易风险。同时，2024年度公司净利润为-5971.17万元，2025年半年度预计净利润为-5500万元至-4600 万元，将出现亏损。 ...

济民健康(603222)今日涨停，全天换手率31.31%，成交额18.28亿元，振幅19.56%。龙虎榜数据显示， 营业部席位合计净买入6344.57万元。 上交所公开信息显示，当日该股因日振幅值达19.56%、日换手率达31.31%上榜，营业部席位合计净买 入6344.57万元。 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | | | 元） | 元） | | 买一 | 国泰海通证券股份有限公司总部 | 6791.60 | | | | 摩根大通证券(中国)有限公司上海银城中路证券营业部 | 5517.14 | | | 买三 | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券 营业部 | 3992.07 | | | 卖 买二 | | | | 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交4.08亿元，其中，买入成交额为2.36亿 元，卖出成交额为1.72亿元，合计净买入6344.57万元。 具体来看，今日上榜营业部中，第一大买入营业部为国泰海通证券股份有限公司总部，买入金额为 6791.60万元，第一大卖出营业部为浙商 ...

Core Viewpoint - Jimin Health (603222.SH) reported a significant decline in revenue and incurred losses in the first half of the year, primarily due to external factors and inventory adjustments [1] Financial Performance - The company achieved total operating revenue of 366.44 million yuan, a decrease of 21.30% compared to the same period last year [1] - The medical services segment generated revenue of 168.62 million yuan, down 4.80% year-on-year [1] - The medical device segment reported revenue of 75.10 million yuan, a substantial decline of 47.54% year-on-year [1] - The large-volume infusion segment earned revenue of 121.35 million yuan, reflecting a decrease of 15.50% year-on-year [1] Profitability - The company recorded a net loss attributable to shareholders of 52.70 million yuan and a net loss of 53.20 million yuan after excluding non-recurring gains and losses [1] - The losses were primarily attributed to the impact of U.S. tariff policies and the "He Qinghong stamp incident," which significantly reduced revenue and profits from medical devices [1] - Additionally, the company increased inventory write-down provisions for pre-filled catheter flushing devices and safety syringes based on market sales conditions [1]

济民健康管理股份有限公司2025 年半年度报告 公司代码：603222 公司简称：济民健康 济民健康管理股份有限公司 2025 年半年度报告 1 / 155 济民健康管理股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人李丽莎、主管会计工作负责人杨国伟及会计机构负责人（会计主管人员）王合 微声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 报告期，公司不进行利润分配及资本公积转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，敬 请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的 ...

济民健康公告，2025年上半年营业收入3.66亿元，同比下降21.30%。净利润亏损5269.59万元，上年同 期净利润2544.5万元。报告期，公司不进行利润分配及资本公积转增股本。 ...

证券之星消息，8月20日医疗器械板块较上一交易日上涨0.06%，济民健康领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。医疗器械板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603222 | 济民健康 | 11.86 | 10.02% | 164.39万 | | 18.28亿 | | 300642 | 透景生命 | 24.81 | 7.45% | 35.17万 | | 8.65 Z | | 688581 | 安杰思 | 87.93 | 6.07% | 2.57万 | | 2.20亿 | | 301093 | 华兰股份 | 34.04 | 4.58% | 13.19万 | | 4.45亿 | | 600645 | 中源协和 | 29.66 | 3.27% | 23.37万 | | ...

Group 1 - The A-share market saw a total of 104 stocks hitting the daily limit up on August 20, with notable performances in various sectors [1][2] - Jimin Health in the medical device sector achieved a five-day consecutive limit up, indicating strong investor interest [1] - Other sectors with significant performances included consumer electronics with Kosen Technology achieving four consecutive limit ups, and the liquor sector with both Jiugui Liquor and *ST Yanshi achieving two consecutive limit ups [1][2] Group 2 - The list of stocks with consecutive limit ups includes: - Jimin Health (5 days, Medical Devices) - Kosen Technology (4 days, Consumer Electronics) - Hanzhong Precision (4 days, Data Center) - Jiugui Liquor (2 days, Liquor) - *ST Yanshi (2 days, Liquor) [1][2]

Group 1 - The Science and Technology Innovation 50 Index rose over 3%, reaching a new high for the year, driven by a collective surge in chip stocks [1] - Companies such as Jimin Health, Hanzhong Precision Machinery, and Kesen Technology have seen consecutive trading gains, with Jimin Health achieving a five-day streak [1] - The AI server market is dominated by Inspur Information, which holds over 50% market share in China and has reported a 64.39% year-on-year increase in net profit for the first quarter [1] Group 2 - The domestic leading companies are making significant advancements, with Nvidia reportedly developing an AI chip specifically for the Chinese market [3] - Companies like Fullchai Power and Yuanlin Co. have also seen consecutive trading gains, indicating strong market performance [3] - The company Guangxin Technology is a leader in optical modules and has partnered with Cisco to launch a 1.6T silicon optical module [3] Group 3 - The domestic automotive sector is witnessing significant developments, with China FAW planning to acquire approximately 10% of Leap Motor [6] - Companies like Mould Technology and Shentong Express are also making strides, with Mould Technology providing components for new energy vehicles [6] - The automotive thermal management sector is led by companies like Hanzhong Precision Machinery, which specializes in compressors and refrigeration products [8] Group 4 - The pharmaceutical industry is seeing a surge in domestic innovative drugs going global, with Tianmu Pharmaceutical being the first listed company in traditional Chinese medicine [7] - Companies like Huahai Pharmaceutical are advancing in the development of innovative drugs, with over 20 projects currently in research [7] - The automotive passive safety system sector is represented by companies like Songyuan Safety, which reported a 30.85% year-on-year increase in net profit [7]